Our take
Stereotaxis has the longest clinical record of any company in this group. Its robotic magnetic navigation steers a soft catheter inside the heart with magnets rather than by hand, and more than 100,000 patients have been treated with its technology at over 100 hospitals.1 For electrophysiology programs that want robotic precision in ablation, it is the established option.
The company is small and still losing money. Revenue was $32.4 million in 2025, up 20%, with $13.4 million in cash and no debt at year end. Hospitals buying a system should weigh the vendor's finances along with the clinical case.2,3
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Stereotaxis and what it's for
Stereotaxis sells to hospital electrophysiology departments that treat arrhythmias such as atrial fibrillation, atrial flutter, and ventricular tachycardia. Physicians at Baptist Health Lexington in Kentucky first used robotic magnetic navigation clinically in 2003.5,6
Recent installs include Hungary's first system at the University of Szeged, which treated more than 70 patients in its first month, and Latvia's first at Pauls Stradiņš Clinical University Hospital in Riga in October 2026.6,7 Buyers compare robotic magnetic navigation with manual catheter ablation, which remains the standard approach.
Magnets steer the catheter
The Genesis RMN system holds its magnets on flexible robotic arms. The newer GenesisX is semi-mobile: Stereotaxis says it can be set up in a cath lab over a weekend, shields its magnetic field when parked, needs no lab modifications, and can be removed without lasting impact on the room.4
Synchrony puts all cath lab systems on one large display controlled by a single keyboard and mouse, and SynX adds cloud connectivity for remote monitoring, training, and support.4
Catheters drive recurring revenue
MAGiC is a robotically navigated ablation catheter, and MAGiC Sweep is a high-density mapping catheter with 20 electrodes. MAGiC Sweep is not CE marked and is not sold in Europe.4
Disposables, service, and accessories brought in $22.2 million of 2025 revenue, against $10.2 million from systems. System backlog stood at $9.1 million entering 2026, and the company expects 2026 revenue above $40 million.2
Capital equipment sold by quote
Stereotaxis does not publish system or catheter prices. Robots are sold to hospitals as capital equipment and priced by negotiation.2
Competition
Stereotaxis' annual report says its main competition is not another robot but conventional catheter ablation, including radiofrequency, cryo, and pulsed field ablation. It also reports that Johnson & Johnson's obligation to supply its catheters for use with Stereotaxis systems lapsed on December 31, 2025. The companies below sell those manual approaches.9
| Company | Product | Pricing model | Deployment footprint | Where Stereotaxis wins or loses |
|---|---|---|---|---|
| Stereotaxis | Genesis robotic magnetic navigation and MAGiC catheters | Capital system sale, plus per-procedure disposables, service, and software updates9 | More than 100,000 patients treated at over 100 hospitals1 | Only commercial robotic catheter navigation; small vendor facing large incumbents |
| Johnson & Johnson MedTech (CARTO) | CARTO 3 mapping system and ablation catheters10 | Not published10 | Clinical specialists support cases in the lab10 | J&J wins on scale and a full mapping and catheter line. Stereotaxis wins on robotic catheter control. |
| Boston Scientific (FARAPULSE) | FARAPULSE pulsed field ablation platform11 | Not published11 | More than 500,000 patients treated11 | Boston Scientific wins on fast, single-shot pulsed field procedures. Stereotaxis wins in complex cases that need fine catheter steering. |
| Medtronic (PulseSelect and Sphere-9) | Pulsed field ablation systems12 | Not published12 | Registry of 1,160 PulseSelect patients at 38 sites12 | Medtronic wins on breadth of ablation tools. Stereotaxis wins as the only commercial robotic navigation option. |
Source: Robotics Reviewed analysis of company product pages, filings, and announcements, October 2026.
Limits
No public pricing.2
Thin margins on hardware: system gross margin was 21% in 2025, and the company reported an adjusted net loss of $8.8 million for the year.2
Availability varies by country. Stereotaxis notes that its technologies are not for sale in all geographies.4
What customers say
Where it helps
Treating over seventy patients in our first month is an exciting achievement and reflects both the dedication of our team and the need for advanced arrhythmia care in our community.
We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics.
Where it falls short
We found no independent physician or hospital reviews to quote. The concerns in Stereotaxis' own filings are continuing losses, low system margins, and product availability that varies by region.2,4
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Stereotaxis financial results, product pages, and hospital announcements.
Leadership
David Fischel
Chairman and chief executive officerFischel led an investment in Stereotaxis in 2016 and has been chief executive and chairman since February 2017, after more than eight years investing in medical devices at DAFNA Capital Management.8
Sources
- Stereotaxis, Investor relations overview, accessed October 31, 2026
- Stereotaxis, Stereotaxis reports 2025 full year financial results, March 9, 2026, accessed October 31, 2026
- Stereotaxis, Earnings release exhibit 99.1, SEC, March 9, 2026, accessed October 31, 2026
- Stereotaxis, Products, accessed October 31, 2026
- Stereotaxis, About us, accessed October 31, 2026
- Stereotaxis, University of Szeged celebrates strongest first month of robotic cardiology program, September 3, 2026, accessed October 31, 2026
- Stereotaxis, Stereotaxis announces first robotic magnetic navigation system in Latvia, October 22, 2026, accessed October 31, 2026
- Stereotaxis, David Fischel management profile, accessed October 31, 2026
- Stereotaxis, Form 10-K for fiscal 2025, SEC, March 12, 2026, accessed October 31, 2026
- J&J MedTech, CARTO System overview, accessed October 31, 2026
- Boston Scientific, Electrophysiology, accessed October 31, 2026
- Medtronic, Positive results from real-world registries for the Sphere-9 catheter and PulseSelect PFA System at APHRS 2026, October 22, 2026, accessed October 31, 2026
- Stereotaxis, Board and management, accessed October 31, 2026
